Open position as Assistant Professor and Group Leader at Lund University (Lund, Sweden) 

Area: Neurodegenerative disease research, with focus on disease mechanisms.

Faculty affiliation: Medical Faculty

5-years position with the opportunity for promotion to permanent employment as a senior lecturer.

  • The salary is covered by Lund University
  • Several forms of support will be provided by the strategic research area MultiPark (multidisciplinary research on neurogenerative diseases, https://www.multipark.lu.se)

How to apply

Applications are to be made electronically via Lund University’s applications portal by August 17, 2025:https://lu.varbi.com/en/what:job/jobID:831173/?where=36

Eligibility

  • Applicants should have obtained a doctoral degree within 7 years from the closing date for the applications (i.e., not earlier than 2018) . An earlier doctoral-degree date is acceptable if there are documents proving parental leave, military service, illness, or other significant circumstances that have prevented the candidate from working as a researcher after graduation.
  • The candidate should have several years of experience in biomedical-related research, having carried out a postdoctoral training in an international environment outside of Sweden.
  • Research in the field should have resulted in publications at a high scientific level.

For additional information you may contact Angela Cenci Nilsson, MultiPark Director , [email protected]

Open position as Assistant Professor and Group Leader at Lund University (Lund, Sweden)  Read More »

Postdoc opportunity in the Trudeau lab in Montreal to study dopamine neuron biology and vulnerability

Exploring the fundamental mechanisms of dopamine release and dopamine neuron
vulnerability
Supervisor: Dr. Louis-Eric Trudeau


A postdoc position is presently available in the laboratory of Dr. Louis-Eric Trudeau at the
University of Montreal to work on projects that focus on the fundamental mechanisms of
dopamine release and on the vulnerability of these neurons in Parkinson’s disease models.
The ideal applicant is someone who recently completed (or is very close to completing) a
Ph.D. in the field of neuroscience, has experience in the use of mouse models and
techniques such as fluorescence-based approaches, electrophysiology/electrochemistry
and the use of viral vectors. Accomplishments in the form of peer-reviewed publications is
also expected. The successful candidate will work on exploring the molecular mechanisms
that mediate different forms of dopamine release and the links between dopamine neuron
connectivity and their vulnerability in Parkinson’s disease models. The work with involve a
range of state-of-the-art techniques including mouse genetics, genetically encoded
neurotransmitter sensors, in vitro and in vivo models and a range of fluorescence imaging
approaches. Competitive salary support will be provided. The Université de Montréal is one
of the top research universities in Canada and the city of Montreal offers an ideal
combination of critical mass in the field of neuroscience and quality of life. The applicant is
also expected to apply the University of Montreal Center for Biomedical Innovation
postdoctoral fellowship competition (https://cibmontreal.ca/en/news/launch-of-the-2025-
postdoctoral-fellowship-competition/) (deadline May 27).


Contact: [email protected].
https://www.labotrudeau.org/
https://pubmed.ncbi.nlm.nih.gov/?term=Trudeau+LE&sort=date

Postdoc opportunity in the Trudeau lab in Montreal to study dopamine neuron biology and vulnerability Read More »

New Publication: Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa-Induced Dyskinesia

Authors: Abdolaziz Ronaghi, Tiberiu Loredan Stan, Sebastian A. Barrientos, Pär Halje, Azat Nasretdinov, Luciano Censoni, Sebastian Sulis Sato Evgenya Malinina, Joakim Tedroff, Nicholas Waters, Per Petersson

Abstract: Levodopa provides effective symptomatic treatment for Parkinson’s disease. However, nonmotor symptoms are often insufficiently relieved, and its long-term use is complicated by motor fluctuations and dyskinesia. To clarify mechanisms of levodopa-induced dyskinesia and pharmacological interventions aimed at reducing dyskinetic symptoms, we have here characterized the neurophysiological activity patterns in sensorimotor and cognitive-limbic circuits in dyskinetic rats, comparing the effects of amantadine, pimavanserin, and the novel prospective antidyskinetic and antipsychotic treatment mesdopetam. Parallel recordings of local field potentials from 11 cortical and subcortical regions revealed suppression of narrowband gamma oscillations (NBGs) in sensorimotor structures by amantadine and mesdopetam in conjunction with alleviation of dyskinetic signs. Concomitant gamma oscillations in cognitive-limbic circuits were not directly linked to dyskinesia and were not affected by antidyskinetic treatments to the same extent, although treatment-induced reductions in functional coupling were observed in both sensorimotor and cognitive-limbic circuits, in parallel. In a broad frequency spectrum (1-200 Hz), mesdopetam treatment displayed greater similarities to pimavanserin than to amantadine. These findings point to the reduction of NBGs as a valuable biomarker for the characterization of antidyskinetic treatment effects and provide systems-level mechanistic insights into the antidyskinetic efficacy of mesdopetam, with potential additional benefits for the treatment of Parkinson’s-related psychosis.

DOI: 10.1111/ejn.70032

New Publication: Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa-Induced Dyskinesia Read More »

Membership meeting (annual meeting)

To keep the Swebags society running smoothly and to continue offering webinars and other activities, we rely on the voluntary efforts of our board members. The board is elected during our annual meeting, and your participation is crucial to ensure the society’s success. No registration is required—just join us at the scheduled time.

Date: 2024-12-05
Time: 08:30 – 09:00
Link: https://kth-se.zoom.us/j/64834058661?pwd=8ZsapRbiGmVmJKhazh0OzPpnan758M.1


Agenda:
Opening of Meeting/Welcome
Adoption of the Agenda
Decide on two persons that certify the meeting protocol and count votes in case of voting procedures.
Elect meeting chairperson and meeting secretary
Proof of Notice of Meeting Given
Voting list adjustment
Previous minutes
Evaluate the reports from the board etc. and decide if there is a continued trust in the board.
Presentation of Annual Report for 2023
Presentation of Operational plan for 2024
Discharge from liability for the board
Elections
Elect Chair (for 1 year)
Elect Board members (for 3 years)
Elect two accountants and 2 stand-ins for the accountants. (for 1 year)
Elect nomination committee and one stand-in for these (for 1 year)
Honorary members
Motions and Bills
Decide on membership fees.
Any other business
Adjournment

Membership meeting (annual meeting) Read More »

Extended Abstract Submission Deadline

We understand that many of you have tried to submit an abstract and register for the conference via the SWEBAGS website without succeeding. We sincerely apologize for the inconvenience caused by the downtime of our website. We are pleased to inform you that the issue has been fully resolved, and our site is now back online.

Given the circumstances, we have decided to extend the abstract submission deadline through September 30th.

If you have already prepared your abstract, you can now submit it through our website: SWEBAGS Conference 2024 Submission. For those who haven’t yet, we encourage you to take advantage of this extended deadline to share your latest research on basal ganglia-related topics.

Extended Abstract Submission Deadline Read More »